Media Releases › INOVIQ

• SubB2M-based Surface Plasmon Resonance (SPR) test to be developed with Nicoya on the Alto™ Digital SPR instrument
• Contract sales force appointed via agreement with Percorso Life Sciences to accelerate sales of EXO-NET research tools in USA
• U.S. Patents granted for SubB2M and hTERT technologies
• SubB2M immunohistochemistry (IHC) research study detected melanoma with 91% sensitivity
• Mark Edwards appointed Chief Financial Officer (CFO) and Company Secretary, effective 2 November 2022, succeeding Tony Di Pietro
• Cash balance of $13.5m as at 30 September 2022; R&D tax incentive refund of $865k received post quarter end